Citations

Clear

3641 citation(s) found for "South, AP".

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE
Crew, Katherine D. , Arnold, Kathryn B. , Dzingle, Sam, Michel, Alissa, DeLucie, Michael, Law, Cynthia W., Pruthi, Sandhya , Leon, Ana C Sandoval, Shirley, Rachel, Perdekamp, Maria T Grosse, Colonna, Sarah V, Krisher, Stacy L, King, Tari A. , Yee, Lisa D. , Braun-Inglis, Christa, Mangino, Debra A. , Wisinski, Kari B. , DeYoung, Claudia A, Ross, Masey, Floyd, Justin D., Kaster, Andrea, VanderWalde, Lindi, Saphner, Thomas J. , Zarwan, Corrine, Lo, Shelly, Graham, Cathy, Conlin, Alison, Yost, K. , Agnese, Doreen M, Jernigan, Cheryl, Neuhouser, Marian L, Arun, Banu, Pruthi, Sandhya , Anderson, Garnet L. , Michel, Alissa , DeLucie, M. T., Sandoval-Leon, Ana Cristina , Shirley, Rachel, Perdekamp, Maria T. Grosse, Colonna, Sarah V. , Krisher, Stacy, Ballinger, Tarah Jean , Braun‐Inglis, Christa , Ross, Masey, Graham, Cathy Lynne , Yost, Kathleen J. , Agnese, Doreen Marie , Hershman, Dawn L. , Zell, Jason A. , Kukafka, Rita

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag216 | PMID 42391096 Get It

Abstract Background Breast cancer chemoprevention is underutilized among high-risk women. We examined whether decision support could increase informed decision making. Methods We conducted a cluster randomized controlled trial to evaluate the effect of a patient-facing decision aid (RealRisks) and provider tool (BNAV) compared with standard education on the number of women with high-risk breast lesions making informed choices. Questionnaires were administered at baseline and 6 and 12 months. The primary outcome was chemoprevention informed choice (defined as adequate knowledge and attitudes congruent with decision) at 6 months. Secondary endpoints included breast cancer risk perceptions, worry, chemoprevention knowledge, decision conflict, and chemoprevention decision. Results Across 31 randomized sites, we enrolled 210 providers, who were primarily breast health specialists. Of these, 24 sites (14 intervention, 10 control) enrolled 412 patients. Among 287 patients evaluable for the primary outcome, there were no statistically significant differences in informed choice between the intervention and control arms at 6 months (35% vs 27%, respectively; P = .20) and 12 months (37% vs 25%, respectively; P = .05). At 6 months, women in the intervention compared with control arm were more likely to have accurate breast cancer risk perceptions (31% vs 21%, respectively; P = .03) and adequate chemoprevention knowledge (33% vs 23%, respectively; P = .04). At 12 months, 52% of women in the control and 50% in the intervention arm self-reported initiating chemoprevention. Conclusion Decision support led to modest improvements in accurate risk perceptions and chemoprevention knowledge but not informed choice. Relatively high chemoprevention uptake was achieved among women with high-risk breast lesions managed mainly by breast health specialists. Trial Registration NCT04496739, https://clinicaltrials.gov/study/NCT04496739?cond=NCT04496739&viewType=Card&rank=1
Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season
Zambrano, Laura, Newhams, Margaret M., Payne, Amanda B., Orzel-Lockwood, Amber O., Halasa, Natasha B., Calixte, Jemima, Chiotos, Kathleen, Crandall, Hillary , Cameron, Melissa A. , Coates, Bria M. , Michelson, Kelly N., Schuster, Jennifer E., Nofziger, Ryan A. , Chauhan, Jigar C., Maamari, Mia , Kong, Michele, Martine, Lora M., Guzman‐Cottrill, Judith A. , Bhumbra, Samina S. , Irby, Katherine , Staat, Mary Allen, Bradford, Tamara T. , Wellnitz, Kari, Ml, Stockwell, Zinter, Matt, Hymes, Saul, Levy, Emily R. , Biggs, Austin , Lindsey, Katherine, Campbell, Angela P., Simeone, Regina M. , Zambrano, Laura D. , Newhams, Margaret M. , Payne, Amanda B. , Halasa, Natasha , Calixte, Jemima M., Maddux, Aline B. , Chiotos, Kathleen , Kamidani, Satoshi , Zerr, Danielle M. , Gertz, Shira J. , Michelson, Kelly Nicole , Schuster, Jennifer E. , Chauhan, Jigar , Shein, Steven L. , Kong, Michele , Hume, Janet R. , Staat, Mary Allen , Wellnitz, Kari , Zinter, Matt S. , Schwartz, Stephanie P. , Hymes, Saul, Lindsey, Katherine N. , Campbell, Angela P. , Randolph, Adrienne G.

Mayo Clinic

No container title available | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.26.26356705 Get It

Abstract Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children <2 years of age. RSV immunization with infant monoclonal antibody or maternal vaccine is recommended to protect all U.S. infants in their first RSV season. For certain high-risk children aged 8−19 months entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-associated respiratory failure in children during their second season. Objectives To describe children admitted to the pediatric intensive care unit (PICU) for RSV during their second RSV season by preexisting health conditions, and to compare demographic and clinical characteristics across groups. Design, Setting, and Participants Surveillance registry of children 8-<24 months old admitted to the PICU in 30 pediatric hospitals in the 2023-2024/2024-2025 RSV seasons. All children had an RSV-positive respiratory sample and received respiratory support with high flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation (IMV). Exposure Preexisting health conditions potentially increasing risk of severe RSV disease. Main Outcomes and Measures Patients were classified into four mutually exclusive groups by preexisting health conditions: 1) U.S. nirsevimab eligible criteria, 2) other identified RSV risk conditions (with some evidence of increased risk for severe RSV), 3) other preexisting conditions, and 4) no preexisting conditions. Patient demographic characteristics and level of respiratory support received were compared. Results Among 574 children: 47 (8.2%) had U.S. nirsevimab eligibility criteria, 76 (13.2%) had other RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. A higher proportion of children with nirsevimab eligibility factors (40.4%) than those with other identified RSV risk conditions (17.1%) required IMV, which was higher than other (10.4%) or no (5.9%) preexisting health conditions (p trend <0.001). Conclusions and Relevance Approximately 20% of children admitted to the PICU with severe RSV were in the defined groups that met U.S. nirsevimab-eligibility criteria or that had an identified RSV risk condition associated with known risk for severe RSV. A considerable proportion of both groups of children required IMV for respiratory support. These findings may help inform future deliberations regarding U.S. second season nirsevimab-eligibility recommendations. Key Points Question What preexisting health conditions are present in children aged 8–<24 months admitted to the pediatric intensive care unit for severe RSV disease in their second RSV season and how do clinical outcomes differ? Findings Among 574 children, 8% were eligible for nirsevimab in the U.S. and 13% had other preexisting conditions with known risk for severe RSV. Children with preexisting conditions, particularly those eligible for nirsevimab, were more likely to require invasive mechanical ventilation than those without. Meaning These findings may inform future deliberations regarding which children in their second RSV season might benefit from RSV preventive products.
Robotic Assisted Bronchoscopy with Endobronchial Ultrasound for the Evaluation of Multiple Pulmonary Nodules: A Multi-Center Registry
Kapp, Christopher M. , Wahidi, Momen M, Rowell, J. M., Yong, Sylvia S, Seides, Benjamin, Smith, Sean B. , Balan, Bharat, DiBardino, David, Haas, K, White, Brian, Kim, Jeremy , Guiance, Irene Riestra , Bhargava, Rohan , Diaz, Natalia H, Trujillo, D. Abia, Silvestri, G, Liu, Yupeng, Pfister, Courtney, Thiboutot, Jeffrey, Lee-Mateus, Alejandra Y, Abia Trujillo, David, Wahidi, Momen M. , Rowell, Jamie H, YONG, SYLVIA S, DiBardino, David M. , Haas, Kevin P. , Diaz, Natalia, Lee‐Mateus, Alejandra Yu , Thiboutot, Jeffrey P.

Mayo Clinic

Annals of the American Thoracic Society | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/annalsats/aaoag142 | PMID 42366642 Get It

Abstract Introduction Multiple pulmonary nodules (MPNs) are commonly encountered in patients at elevated risk for thoracic malignancy and represent a spectrum of disease states and stages. We evaluated the safety, and procedural outcomes of a combined robotic assisted bronchoscopy (RaB) and linear endobronchial ultrasound (EBUS) approach to patients with MPNs during a single bronchoscopic procedure. Methods This multicenter observational registry included patients who underwent RaB for evaluation of MPNs. Data were prospectively collected from six centers between 2019 and 2025. Demographics, imaging characteristics, safety events, and procedural outcomes were analyzed and associated with final diagnosis. Results A total of 191 patients underwent RaB with biopsy of MPN during a single procedure; 167 patients also underwent linear EBUS lymph node sampling. The strict per nodule diagnostic yield was 71.5% overall (first nodule 70.7%, second 74.3%, third 71.4%). At least one malignant nodule was identified in 127 patients (66.8%), and 85 patients (44.5%) had two or more malignant nodules; 15 patients (17.6%) demonstrated heterogeneous histopathology between malignant nodules. Among patients with non–small cell lung cancer, adequate cellularity for next generation sequencing was achieved in 82.6% of nodules. Malignant lymph nodes were identified in 10.8% (18/167). No patients with two pure ground glass nodules (0/8) had malignant nodal involvement. Pneumothorax occurred in 7.3% of cases, with 2.1% requiring chest tube placement; unplanned admissions occurred in 3.7%. Conclusion This study provides a large multisite registry evaluation of performance of simultaneous bronchoscopic sampling of multiple pulmonary nodules with EBUS staging during a single anesthesia event demonstrating an acceptable safety profile and adequacy for molecular profiling.
Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
Desai, M Y, Nagueh, S F, Giudicessi, J O H N R, Kellner, D, Pollman, M, Varfaj, B, Paterson, N A T, Harrison, W, Pushkin, R, Tomlinson, L T, Mangal, B, Argast, G, Lombardi, L, Ivey, K, Tingley, W, Desai, M Y, Nagueh, Sherif F. , Giudicessi, John R. , Kellner, Danielle, Pollman, Matthew J., Paterson, N A T, Tomlinson, LaTanya, Argast, Gretchen, Tingley, Whit

Mayo Clinic

European Journal of Heart Failure | June 29, 2026 | Volume: 28 | Issue: Supplement_2 | Pages: No page available

10.1093/ejhf/xuag193.1205 Get It

Abstract Background Immunosuppression (IS) is required in AAV-mediated gene therapy to maximize safety and efficacy, in part to mitigate potential hepatotoxicity and prevent immune-mediated loss of transgene expression. However, prolonged IS increases the risk of complications, including infections. MYBPC3-associated HCM patients have limited treatment options. MyPEAK-1 is a first-in-human trial to assess the safety and efficacy of TN-201, a gene replacement therapy, which was designed to address the underlying genetic cause of MYBPC3-associated HCM in symptomatic adults. Objective To describe the safety and refinement of the IS regimen and monitoring used during the dosing of Cohorts 1 and 2 in the MyPEAK-1 trial. Methods The dose-escalation study utilized two cohorts (n=3 each) receiving 3E13 vg/kg (Cohort 1) or 6E13 vg/kg (Cohort 2) of TN-201 as a single IV infusion. All patients received prophylactic prednisone (starting at 1 mg/kg, maximum 80 or 60 mg/day) and sirolimus (target trough level of 4–8 ng/mL). Prednisone was tapered over several weeks, with variable timing depending on safety laboratory results. The dose of prednisone and timing of sirolimus were adjusted to reduce IS burden in Cohort 2. Specifically, sirolimus was initiated earlier (Day -7 vs Day -3) and the maximum starting dose of prednisone was reduced (from 80 to 60 mg/day). Monitoring frequency was increased to weekly throughout the course of IS. An independent data safety monitoring board provided safety oversight. Results All six patients successfully completed the IS regimen. TN-201 was generally well-tolerated at both dose levels (follow-up &gt;52 weeks and &gt;12 weeks in Cohort 1 and 2, respectively). Adjustments to the IS regimen and monitoring during Cohort 1 facilitated a significantly shorter course of IS in Cohort 2, with a mean duration of prednisone use of 256 vs 81 days. Despite receiving a higher dose of TN-201, peak transaminase levels, reflecting liver inflammation, were lower in Cohort 2 than Cohort 1. There was no clinical TMA in either cohort. Mean sirolimus trough levels remained consistent between groups (7.2 vs 7.4 ng/mL). Increases in MyBP-C protein, decreases in circulating cardiac biomarkers, and a reduction in LV hypertrophy were observed during follow up. Conclusion Standardized adjustments to the prophylactic immunosuppressive regimen in the MyPEAK-1 trial successfully managed the immunogenicity of AAV9-based gene therapy. Cohort 2 patients required lower cumulative corticosteroid doses without compromising safety or cardiac transduction. These refinements enabled lower cumulative steroid exposure and shorter IS durations in the higher-dose cohort. These results suggest that individualized, protocol-driven IS is effective in controlling the immune response to TN-201 while supporting transgene expression, paving the way for continued investigation of this gene therapy clinical investigation in MYBPC3-associated HCM population.Corticosteroid duration and daily doseFor image description, please refer to the figure legend and surrounding text.
Age- and sex-associated cardiac features and diagnostic latency in patients with ATTR-mixed and PN phenotypes assessed in a prospective multi-national real-world study
Davis, M K, Grogan, M, Hahn, K, Masri, A, Wright, J, Shivappa, N, Sundin, A K, Natman, J, Smith, J G, Gillmore, J D, Davis, Margot K. , Grogan, M, Hahn, Katrin , Wright, Jason, Sundin, Anna-Karin , Nåtman, Jonatan , Smith, J G, Gillmore, Julian D.

Mayo Clinic

European Journal of Heart Failure | June 29, 2026 | Volume: 28 | Issue: Supplement_2 | Pages: No page available

10.1093/ejhf/xuag193.246 Get It

Abstract Background Age and sex influence the clinical expression of transthyretin (ATTR) amyloidosis, but limited evidence exists on their real-world impact across disease phenotypes. The prospective, multi-national MaesTTRo study, currently enrolling patients from the USA, Canada, the UK, Germany and Spain, provides a uniquely comprehensive opportunity to explore age- and sex-associated differences in routine practice. The aim of this analysis was to quantify the associations between these factors and diagnostic delay and cardiac findings. Methods Baseline data from 230 consecutively enrolled patients were analysed. Cohorts were stratified by age at diagnosis (&lt;60 y, n = 45; ≥60 y, n = 185) and separately by sex (female n = 70; male n = 161). Clinical characteristics, laboratory values, echocardiographic parameters and Kansas City Cardiomyopathy Questionnaire (KCCQ-23) scores were compared descriptively. Additional data will be included in the presentation as enrollment continues. Results Younger patients exclusively expressed a hereditary genotype (100% vs 63%), and experienced a longer mean (+SD) diagnostic delay than older patients (48 ± 61.5 vs 40.9 ± 64.4 months). Cardiac involvement was markedly age-dependent: median NT-proBNP was 91.5 pg ml⁻¹ (IQR 48.5–307) in the &lt;60 yrs group versus 1,393.5 pg ml⁻¹ (457–3,065) in the ≥60 yrs group. Older patients were more likely to experience New York Health Association (NYHA) class II–IV limitation than younger patients (88% vs 44%). Nonetheless, LV ejection fraction remained preserved in both cohorts (51 ± 14.8 vs 55.6 ± 9.3%). Older patients also reported a higher burden of cardiac symptoms (52% vs 33%). Patient-reported KCCQ scores were lower in the ≥60 yrs group vs &lt;60 years (68.4 ± 22.3 vs 73.3 ± 27.4). Females were more often diagnosed with ATTRv (84% vs 63%) after longer delays (51.3 ± 80.9 vs 38.3 ± 54.6 months), despite a stronger family history (61% vs 34%), and had lower biomarkers (NT-proBNP: 589 pg ml⁻¹ [111–2,509] vs 1,220 pg ml⁻¹ [386–2,941]) and wall thickness (LV wall thickness &gt;12 mm: 58% vs 73%), although there was no difference in LV mass index. Males reported better health status (KCCQ: 70.7 ± 22.2 vs 64.7 ± 24.4). Neurologic manifestations were common in both sexes (~70%), while musculoskeletal symptoms were more commonly reported in females (33% vs 23%). Conclusions Age and sex may independently modulate the diagnostic trajectory and cardiac presentation of ATTR amyloidosis. Advanced age and male sex are associated with more pronounced structural biomarker evidence of myocardial damage, whereas younger age and female sex are linked to delayed diagnosis of primarily hereditary ATTR amyloidosis with polyneuropathy and less cardiac involvement, especially when non-indexed echo measurements are used. These results underscore the need for age- and sex-specific approaches to prompt early clinical suspicion and diagnosis in order to enable treatment to mitigate disease progression.For image description, please refer to the figure legend and surrounding text.For image description, please refer to the figure legend and surrounding text.
Reply to “Real‐world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer”
Hanna, Diana L. , Jameson, Gayle , Roe, Denise J. , Borazanci, Erkut, Zoller, Alison R., Rabinowitz, Joshua D., Gately, Stephen, Hoff, Daniel D. Von, Rasco, Drew W., Jameson, Gayle S , Zoller, Alison R , Hanna, Diana L , Roberts, Caroline G. P. , Borazanci, Erkut , Rabinowitz, Joshua D. , Gately, Stephen, Hoff, Daniel D. Von , Rasco, Drew

Mayo Clinic

Cancer | June 26, 2026 | Volume: 132 | Issue: 13 | Pages: No page available

10.1002/cncr.70510 | PMID 42361077 Get It

TDP-43 subtypes shape transcriptomic signatures in Alzheimer’s disease
Wang, Xiaojie, Reeves, Madison M, Bejarano, Jesús González , Song, Yuping , Dunmore, Judy, Yue, Mei, Rawlinson, Bailey, DeTure, Michael, Tome, Raul Baena, Narayan, Anand, Bartfield, Jordan, Graff‐Radford, Neill R. , Peterson, Ronald C. , Oskarsson, Björn, Murray, Melissa E, Dickson, DW, Cook, Casey, Zhang, Yongjie, Petrucelli, Leonard , Josephs, Keith A, Walker, Alyssa C. , Reeves, Madison M., Dunmore, Judy H., Yue, Mei, Rawlinson, Bailey, Engelberg-Cook, Erica , DeTure, Michael , Narayan, Anand, Boeve, Bradley F. , Knopman, David S. , Day, Gregory S. , Murray, Melissa E. , Dickson, Dennis W. , Josephs, Keith A. , Prudencio, Mercedes

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.22.733827 | PMID 42395416 Get It

Abstract TAR DNA-binding protein 43 (TDP-43) pathology frequently co-occurs with Tau neurofibrillary tangles (NFTs) and amyloid β plaques in Alzheimer’s disease (AD), driving significant clinical heterogeneity. Whether TDP-43 engages autonomous molecular programs or instead amplifies Tau-driven neurodegeneration remains difficult to resolve, largely because these pathologies often co-occur. To separate these overlapping signatures, we generated regionally resolved transcriptomic profiles from cognitively normal controls (Controls), neuropathologically defined cohorts of AD, AD with limbic-predominant age-related TDP-43 encephalopathy (AD/LATE), and frontotemporal lobar degeneration (FTLD-TDP), categorizing them by their distinct TDP-43 subtypes (types α and β for AD/LATE; types A and B for FTLD-TDP). By integrating transcriptomic profiles with quantitative measures of phosphorylated TDP-43 (pTDP-43) and Tau (pTau), we separated pathology-associated signals within mixed disease contexts. We found that TDP-43 is linked to distinct transcriptomic programs in AD/LATE that are largely uncoupled from Tau burden and diverge from those observed in FTLD-TDP. These signatures showed regional specificity, with transcriptomic remodeling occurring in the amygdala across both diseases, whereas frontal cortex alterations were largely restricted to FTLD-TDP. Furthermore, by stratifying cases by TDP-43 morphological subtype, we unmasked specific biological trajectories, from immune activation to unique cellular vulnerabilities, that are not apparent in unstratified cohorts. Together, our findings provide a framework for decoupling mixed proteinopathies and demonstrate that TDP-43 shapes autonomous, subtype-dependent transcriptional landscapes in AD.
Hands-on Education to Increase Comfort and Knowledge Utilizing In-Check TM Inhaler Training Device in Medical Trainees
Strother, Robert K. , Miller, Nathaniel E. , Umbreit, Audrey , Lee, Maddie, Smoak, Julia, Firkus, Danielle , Davis, Amanda, Strother, Robert , Miller, Nathaniel E

Mayo Clinic

Journal of Primary Care & Community Health | June 25, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261463360 | PMID 42349020 Get It

Introduction Correct inhaler technique is of utmost importance in the optimal delivery of therapeutics utilized for respiratory illnesses. Previous research suggests that the ability of both patients and providers to correctly use these inhalers is sub-optimal and is associated with poorer patient outcomes. Further education about inhaler types and technique as part of residency education could serve to correct these trends. Methods Family medicine residents were taught correct inhaler technique with an inhaler training device (In-Check TM DIAL G16) using a didactic lecture with hands-on teaching exercise utilizing pharmacy interprofessional teaching. We assessed pre- and post-intervention comfort and knowledge of correct inhaler technique. Results Twenty of twenty-seven eligible family medicine residents attended an interdisciplinary workshop with clinical pharmacists with the purpose of improving inhaler technique comfort level and knowledge. A pre- and post-knowledge test and comfort questionnaire were provided to those participating. Comfort levels with prescribing different inhaler types increased after the intervention and knowledge of different inhalers improved. Conclusion Use of an inhaler training device coupled with an interdisciplinary lecture format improved provider knowledge of correct inhaler technique and comfort with prescribing inhalers.
Accuracy of the rapid‐response electroencephalography's Automated Seizure Burden Estimator: A follow‐up validation study of version 8 ( AccuRASE II )
Sheikh, Zubeda , Fong, Michael W K , Dhakar, Monica B. , Fang, Wei , Ayub, Neishay , Bacic, Janine , Haider, Hiba A. , Foreman, Brandon , Gilmore, Emily J. , Mizrahi, Moshe , Osman, Gamaleldin , Sheikh, Zubeda B , Dhakar, Monica B , Molino, Janine , Karakis, Ioannis , Schmitt, Sarah E , Osman, Gamaleldin , Yoo, Ji Yeoun , Hirsch, Lawrence J , Haider, Hiba A , Ayub, Neishay , Gilmore, Emily , Foreman, Brandon , Karakis, Ioannis , Yoo, Ji Yeoun , Hirsch, Lawrence J.

Mayo Clinic

Epilepsia | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70352 | PMID 42347801 Get It

Abstract Objective Ceribell Inc.'s point‐of‐care electroencephalographic (EEG) system and artificial intelligence‐based Automated Seizure Burden Estimator (ASBE; ClarityPro) have US Food and Drug Administration clearance for diagnosing electrographic status epilepticus (ESE). The AccuRASE study using ASBE version 6 (V6) showed high negative predictive value (NPV) but limited sensitivity and positive predictive value (PPV) at certain thresholds. Version 8 (V8) is the updated algorithm trained with additional EEG samples. Methods We tested V8 on the previously used rapid‐response EEG test dataset (not used to train V8). Sensitivity, specificity, PPV, and NPV were compared against blinded expert annotations. ESE, ESE and possible ESE (ESE/pESE), electrographic seizures (ESz), and Esz with highly epileptiform patterns (Esz/HEPs) at burden thresholds of >1%, >10%, >20%, >50%, and >90% were analyzed. Additionally, we evaluated the built‐in ESE and ESE/pESE alerts (≥90% over 5 min, ≥20% over 1 h, or ≥10 continuous minutes of seizure). Results V8 showed 100% sensitivity at lower thresholds (>10%–20%) for ESE (V6 .86), without a specificity loss (V8 .9 vs. V6 .85), and retained NPV (V8 1.0 vs. V6 .99). Sensitivity at 50% threshold was .86 for ESE (V6 .71), and specificity was .94 (V6 .91); PPV for ESE was 30% for ESE and 80% for ESE/pESE. The specificity for ESE remained high for 90% burden (V8 .96, V6 .97) but the sensitivity dropped (.29 vs. V6 .43). Sensitivity was lower for ESz/HEPs (.54 → .44 at >10% threshold), although the algorithm is not designed to detect HEPs. Built‐in alert analysis showed significantly improved sensitivity for ESE (.57 → .86); specificity and NPV remained high (>.94). Significance ASBE V8 showed meaningful improvements in sensitivity, continued excellent NPV, and improved built‐in alert accuracy for ESE and ESE/pESE. The best seizure burden threshold for ruling out ESE now is 20% (vs. 10% with V6) and that for ruling in ESE/pESE with reasonable certainty is 50% (vs. 90% with V6).